Pharmacologic treatment of downstream of tyrosine kinase 7 congenital myasthenic syndrome.
about
Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromesExpanding genotype/phenotype of neuromuscular diseases by comprehensive target capture/NGS.Inherited disorders of the neuromuscular junction: an update.Postnatal knockdown of dok-7 gene expression in mice causes structural defects in neuromuscular synapses and myasthenic pathology.Congenital Myasthenic Syndrome due to DOK7 mutations in a family from Chile.Utility of next generation sequencing in genetic diagnosis of early onset neuromuscular disorders.The Neuromuscular Junction and Wide Heterogeneity of Congenital Myasthenic Syndromes.
P2860
Q24187268-29E6823D-8940-4BC4-920C-2E167DE18640Q36729177-4B9338D4-63C1-4EB6-B78A-9570CEA58CB0Q38259083-1663EFE7-2F4C-448E-B0C3-FFEF8A864B1FQ40793178-3229A0D9-D7C8-4DEB-BECE-0C020654ECC9Q46531755-82A57070-B911-41B7-A214-91589ACE76D8Q50967429-E0DD6CAA-D9A4-4B6B-B62E-4B4F864946BAQ55661123-99AB0847-47C1-426B-A5CE-EE2EC81EB73E
P2860
Pharmacologic treatment of downstream of tyrosine kinase 7 congenital myasthenic syndrome.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pharmacologic treatment of dow ...... ongenital myasthenic syndrome.
@en
type
label
Pharmacologic treatment of dow ...... ongenital myasthenic syndrome.
@en
prefLabel
Pharmacologic treatment of dow ...... ongenital myasthenic syndrome.
@en
P1433
P1476
Pharmacologic treatment of downstream of tyrosine kinase 7 congenital myasthenic syndrome
@en
P2093
John Vissing
P304
P356
10.1001/JAMANEUROL.2013.5590
P407
P577
2014-01-14T00:00:00Z